REC: CardioClinics最新文献_第10页

El papel del residente en la Sociedad Española de Cardiología: evolución, retos y perspectiva futura 居民在西班牙心脏病学会中的作用：演变、挑战和未来展望

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/j.rccl.2023.07.007

Ana Laffond

引用次数: 0

Vericiguat en el abordaje actual del paciente con insuficiencia cardiaca 验证目前心力衰竭患者的治疗方法

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/j.rccl.2023.07.001

Ángel Manuel Iniesta Manjavacas , María Thiscal López-Lluva , Javier de Juan Bagudá , Carlos Ortiz-Bautista , María Lázaro Salvador , Mikel Taibo Urquía , Pablo Díez-Villanueva , Manuel Gómez Bueno

{"title":"Vericiguat en el abordaje actual del paciente con insuficiencia cardiaca","authors":"Ángel Manuel Iniesta Manjavacas , María Thiscal López-Lluva , Javier de Juan Bagudá , Carlos Ortiz-Bautista , María Lázaro Salvador , Mikel Taibo Urquía , Pablo Díez-Villanueva , Manuel Gómez Bueno","doi":"10.1016/j.rccl.2023.07.001","DOIUrl":"10.1016/j.rccl.2023.07.001","url":null,"abstract":"<div><p>In patients with heart failure and reduced ejection fraction (HFrEF), experiencing heart failure (HF) decompensation represents a true turning point in the evolution of this condition, as it indicates progression of the disease, and is associated with a high risk of death and early hospitalization for HF. Alteration of the soluble nitric oxide-guanylate cyclase pathway plays a fundamental role in the etiopathogenesis and development of HFrEF. Vericiguat is an oral stimulator of the soluble nitric oxide-guanylate cyclase that allows restoring this system. The VICTORIA study was the first large clinical trial to include patients with HFrEF and recent HF decompensation, showing the beneficial effects of adding vericiguat to standard treatment. In the present work, the evidence on this drug is reviewed and a proposal for its practical management is presented. Its good safety profile, as well as the simplicity of its use, will facilitate its implementation in real life.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"58 4","pages":"Pages 314-323"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42799720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comité Organizador y Comité Científico 组织委员会和科学委员会

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/S2605-1532(23)00336-9

引用次数: 0

Comunicaciones 通信

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/S2605-1532(23)00338-2

引用次数: 0

Insights into the management of pulmonary arterial hypertension patients in Spain 西班牙肺动脉高压患者治疗体会

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/j.rccl.2023.04.001

Alberto García-Ortega , María Lázaro , Raquel Utande , Victorio Cuenca

{"title":"Insights into the management of pulmonary arterial hypertension patients in Spain","authors":"Alberto García-Ortega , María Lázaro , Raquel Utande , Victorio Cuenca","doi":"10.1016/j.rccl.2023.04.001","DOIUrl":"10.1016/j.rccl.2023.04.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Accurate risk stratification is pivotal to tailor therapy according to the prognosis of pulmonary arterial hypertension (PAH) patients to positively impact the course of the disease. We conducted a nationwide study to assess how the current European Society of Cardiology/European Respiratory Society guidelines for risk assessment and management of PAH patients are followed in real-world practice in Spain.</p></div><div><h3>Methods</h3><p>Hospital-based physicians answered an online questionnaire describing their yearly caseload of PAH patients and their management of virtual cases scenarios for Word Health Organization functional class (FC) II–III PAH patients.</p></div><div><h3>Results</h3><p><span>The main tests requested for a regular risk assessment were echocardiography, 6-minute walk test, measurement of brain natriuretic peptide/N-terminal pro-B-type natriuretic peptide plasma levels and right heart catheterization. The main treatment prescribed was an oral double-combination therapy with an endothelin receptor antagonist (ERA) and a phosphodiesterase type 5 inhibitor (PDE5i) or guanylate cyclase stimulator. Around 20% of the clinicians would also add the selective prostacyclin-receptor agonist (selexipag) to ERA and </span>PDE5i as initial therapy for FC III patients, and nearly all clinicians (99%) would add a prostacyclin pathway agent to FC III PAH patients presenting multiple new intermediate-risk parameters despite a 6-month dual therapy with ERA and PDE5i.</p></div><div><h3>Conclusions</h3><p>The main decisive factor for the management of PAH patients in Spanish hospitals is their functional class and intermediate-risk parameters. Selexipag was more frequently prescribed than parenteral prostacyclin-analogs in triple-combination therapy for FC II–III PAH patients presenting low-risk and intermediate-risk parameters.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"58 4","pages":"Pages 260-271"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44350225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Calcium plunger extraction with the Penumbra system in type 5 infarction Penumbra系统在5型心肌梗死中的应用

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/j.rccl.2023.03.001

Bayardo Antonio Ordóñez Salazar, Roy Martony Pérez Cambero, Joel Estrada Gallegos, Efraín Arizmendi Uribe

引用次数: 0

Metástasis cardiacas: la importancia del estudio multimodalidad 心脏转移:多模态研究的重要性

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/j.rccl.2023.04.004

Clara Ugueto Rodrigo, Lucía Fernández Gassó, Esther Pérez David

引用次数: 0

Effects of acetylsalicylic acid alone or with omega-3 in patients with chronic coronary artery disease 乙酰水杨酸单独或联合ω-3对慢性冠状动脉疾病患者的影响

REC: CardioClinics Pub Date : 2023-10-01 DOI: 10.1016/j.rccl.2023.07.002

Mônica M. Cartocci , Dikran Armaganijan , Mario H. Hirata , Michel Batlouni , Amanda Guerra De Moraes Rego Sousa

{"title":"Effects of acetylsalicylic acid alone or with omega-3 in patients with chronic coronary artery disease","authors":"Mônica M. Cartocci , Dikran Armaganijan , Mario H. Hirata , Michel Batlouni , Amanda Guerra De Moraes Rego Sousa","doi":"10.1016/j.rccl.2023.07.002","DOIUrl":"10.1016/j.rccl.2023.07.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Antiplatelet agents such as acetylsalicylic acid (ASA) play a prominent role in preventing atherothrombosis. However, low-responsive patients who will not benefit from an increased dosage of this drug, which can cause bleeding and gastrointestinal irritation, need to be identified. Drugs such as omega-3 fatty acids, which enhance the vasodilating condition and diminish platelet aggregation, can potentiate the anti-aggregating effects of ASA, avoiding its side effects. Thus, we assessed the alternative use of 200mg/day of ASA and 100mg/day of this drug combined with 1g of omega-3 in 152 patients with chronic coronary artery disease.</p></div><div><h3>Methods</h3><p>Our analysis included platelet function (ASPItest), TBX2 concentrations (ELISA), and SNPs polymorphisms in the rs3842787 and rs3842798 regions of the <em>PTGS1</em> gene of the COX-1 enzyme and the rs5918 region of the <em>ITGB3</em> gene of the fibrinogen's receptor subunit glycoprotein IIIa.</p></div><div><h3>Results</h3><p>ASPItest detected 38 non-responders. The reduction of ASPItest values was more significant in this group than in responders and fell to levels of responders in non-responders of the 200mg/day treatment. A rare allele of rs3842787 is associated with a worse ASPItest response, and the rare allele of the rs5918 polymorphism with a worse response related to TBX2 concentration. Both treatments showed no statistically significant difference in hematuria or bleeding, constituting safe treatment alternatives, and omega-3 treatment reduced monocyte levels.</p></div><div><h3>Conclusions</h3><p>Our results underscore the usefulness of pharmacogenetics for personalized treatments, avoiding gastrointestinal effects and undesirable bleeding.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"58 4","pages":"Pages 303-313"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46185887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Junta Directiva de la Sociedad Asturiana de Cardiología, Junta Directiva de la Sociedad Gallega de Cardiología, Comité organizador, Comité científico y Comité enfermería 阿斯图里亚心脏病学会董事会，加利西亚心脏病学会董事会，组织委员会，科学委员会和护理委员会

REC: CardioClinics Pub Date : 2023-09-01 DOI: 10.1016/S2605-1532(23)00294-7

引用次数: 0

Junta Directiva SAC 2023, Comité Organizador y Comité Científico SAC 2023董事会，组织委员会和科学委员会

REC: CardioClinics Pub Date : 2023-09-01 DOI: 10.1016/S2605-1532(23)00291-1

引用次数: 0